Director Matthew L. Posard of Halozyme Therapeutics, Inc. filed a Form 4 on November 18, 2026, disclosing the sale of 5,000 shares of common stock under a Rule 10b5-1 trading plan adopted on June 15, 2026.

Key Highlights

  • Reporting person: Matthew L. Posard, identified as a Director of Halozyme Therapeutics, Inc. (NASDAQ:HALO).
  • First transaction: 3,400 shares disposed of on November 18, 2026, at a weighted average price of $96.173 per share, with individual sale prices ranging from $95.680 to $96.590.
  • Second transaction: 1,600 shares disposed of on November 18, 2026, at a weighted average price of $96.974 per share, with individual sale prices ranging from $96.700 to $97.490.
  • Remaining holdings: Following both transactions, Posard directly held 48,609 shares of common stock.
  • Trading plan: Both sales were made pursuant to a written Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026.

Posard's Two-Part Share Sale Under 10b5-1 Plan

According to the filing, Matthew L. Posard, a director of Halozyme Therapeutics, Inc., sold a combined 5,000 shares of common stock on November 18, 2026, in two separate transactions. The first transaction involved the disposal of 3,400 shares at a weighted average price of $96.173, with actual sale prices in the range of $95.680 to $96.590 per share. The second transaction covered 1,600 shares sold at a weighted average price of $96.974, with individual prices ranging from $96.700 to $97.490 per share.

The filing states that both sales were executed pursuant to a written trading plan that Posard adopted on June 15, 2026, in accordance with Rule 10b5-1(c). The form indicates this by checking the box designating the transactions as made under a Rule 10b5-1 contract, instruction, or written plan. All shares were held and sold in direct ownership form.

After the two reported transactions, the filing discloses that Posard beneficially owned 48,609 shares of Halozyme common stock directly. The filing notes that Posard will provide, upon request to the issuer, the SEC staff, or any security holder, information regarding the number of shares sold at each individual price within the stated ranges. The form was signed by James R. Oehler as attorney-in-fact on November 18, 2026.

What Was Disclosed

Halozyme Therapeutics director Matthew L. Posard disclosed the sale of 5,000 shares of common stock on November 18, 2026, under a pre-established Rule 10b5-1 plan, leaving him with 48,609 directly held shares following the transactions.